Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 166Polycystic Ovary Syndrome 23Neoplasm Metastasis 10Osteoporosis 7Neoplasms 6Infertility 6Endometrial Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 5Ovarian Neoplasms 4Breast Carcinoma In Situ 4Arthralgia 4Recurrence 3Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Pain 2Leiomyoma 2Fallopian Tube Neoplasms 2Estrogen Receptor-positive Breast Cancer 2Carcinoma, Lobular 2Bone Diseases, Metabolic 2Uterine Neoplasms 1Patient Acceptance of Health Care 1Ovarian Cysts 1Osteitis Deformans 1Obesity 1Neoplastic Cells, Circulating 1

Interventions

ribociclib 1Tamoxifen 1Letrozole 1Goserelin 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer × Letrozole × Clear all
NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Novartis

Phase 1 Completed
88 enrolled
Breast

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡